Icosapent Ethyl Reduces Atherogenic Markers in High-Risk Statin-Treated Patients With Stage 3 Chronic Kidney Disease and High Triglycerides.
Conclusions: In patients with stage 3 CKD at high CVD risk with persistent high TG despite statins, icosapent ethyl 4 g/day reduced potentially atherogenic and other cardiovascular risk factors without raising LDL-C, with safety similar to placebo. These findings suggest prospective investigation may be warranted.
PMID: 31306043 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Heart | Internal Medicine | Omega 3 | Statin Therapy | Study | Urology & Nephrology